Navigation Links
FDA Announces Voluntary Withdrawal of Pergolide Products

ion is a condition in which valves don’t close tightly, allowing blood to flow backward across the valve. Symptoms include shortness of breath, fatigue and heart palpitations.

In light of this additional post-market safety information, the companies that manufacture and sell pergolide will stop shipping pergolide for distribution and, in cooperation with FDA, will withdraw the products from the market.

Permax was approved in 1988 for Eli Lilly and Company as an adjunctive therapy with levodopa in Parkinson’s disease. Valvular heart disease was first described in association with pergolide in 2002. In 2003, FDA asked Lilly to add valvulopathy (abnormality of cardiac valves) to the warnings section of Permax labeling, at which time a Dear Healthcare Practitioner letter was sent by Lilly. In 2006, the warning was upgraded to a black box warning, the FDA’s strongest form of warning, because of new data concerning risks of heart valve damage.

FDA today is issuing a Public Health Advisory (PHA) detailing the removal of pergolide products from the market. The PHA, which is available at www.fda.gov/cder/drug/advisory/pergolide.htm includes information and recommended actions for physicians, pharmacists and patients.

The effect of the voluntary withdrawal on supplies of pergolide currently in pharmacies will not be immediate. This delay will allow time for health care providers and patients to discuss appropriate treatment options and time to change treatments.

FDA is working with the manufacturers of pergolide to determine if it might be possible, once the drug is withdrawn from the market, to make the drug available under an Investigational New Drug Application (IND) for those few patients who are currently receiving pergolide and who cannot be successfully converted to other available treatments.

Source-Bio-Bio Technlogy
SRM
'"/>




Page: 1 2

Related medicine news :

1. Ramdoss Announces Introduction of RCH-II
2. Britain Announces Third Transfusion Related Mad Cow Case
3. Tibet Announces the Dalai Lama’s Tour of South Americ
4. Indian PM Announces Of Setting Up India Study Center At Tashkent
5. PowderMed Announces Needle-Less Flu Vaccine
6. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Australian Government Announces Survey To Tackle Childhood Obesity
9. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
10. Apollo Announces Research on Indian Cardiac Epidemic
11. Government Announces Steps To Promote Ayurvedic Medicine
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...c Sydney Opera House was added to the list of Worl...truction of Danish architect Jorn Utzon's vision w...w cultural sites given the coveted status by UNESC...ittee, meeting in Christchurch, New Zealand. The ...
...ta, who plays the role of a woman in movie 'Hairsp...him lose weight. The star admits that having to... female character Edna Turnblad in the 2007 remake...turned-movie was the perfect combination to shed t...
...x-girlfriend Kate Middleton's curvaceous figure ha...ays been in style for her slender but athletic fig...In her recent appearances Kate appeared painfully ...y and almost flat chested. And according to specu...
...ent A.P.J. Abdul Kalam Friday called for taking ad...iagnostic tool and of tele-radiology to help the n...e was speaking during a visit to the digital radio...on of India Limited (ECIL), which is working towar...
Other Medicine News:
(Date:9/4/2008)...RICH, Switzerland, September 4 /- Axe...trial to assess the safety and tolerability,of a n...vere pulmonary,infection in cystic fibrosis patien...apeutic agent to be delivered directly to the site...pare the effects of two,different doses of the new...
(Date:9/4/2008)...mg cohort demonstrates potent antiviral activity a...profile -, CAMBRIDGE, Mass., Sept. 4 /PRNewswire-...: IDIX ), a biopharmaceutical company engaged,in ...atment of human viral,and other infectious disease...-of-concept study evaluating IDX899, a non-nucleos...
(Date:9/4/2008)...a Announcements Remain on Schedule with Two Abstra...cal Data Release in November 2008, BRIDGEWATER, N...als,Inc., a specialty pharmaceutical company focu...ic disease, today announced the appointment of,Pet...rectors., Peter Garrambone,s career includes more...
(Date:9/3/2008)... says: Wrong Question Asked. Wrong Children Studie... /PRNewswire-USNewswire/ -- A Centers for Disease,...claims there is no link,between the MMR vaccine an...ys this study does nothing to dispel the growing p... raises several questions concerning design,and me...
Breaking Medicine Technology:Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2CDC Misses Target With Flawed MMR/Autism Study 2Programmed death boosts business 3232 1Programmed death boosts business 3232 2Genomic Health to Present at Bank of America 2008 Healthcare Conference and 7th Annual JMP Securities Research Conference 18761 1Genomic Health to Present at Bank of America 2008 Healthcare Conference and 7th Annual JMP Securities Research Conference 18761 2VIA Pharmaceuticals to Present at Rodman 26 Renshaw 5th Annual Global Healthcare Conference 5223 1Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine 28R 29 28VNP40101M 29 in Combination with Cytarabine 2011 1Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine 28R 29 28VNP40101M 29 in Combination with Cytarabine 2011 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine 28R 29 28VNP40101M 29 in Combination with Cytarabine 2011 3
...E)--Jun 20, 2007 - Materia, Inc., a,catalyst techn...s,metathesis platform to Eisai Co., Ltd., a leadin... discovery and development.,The non-exclusive lice..., and patent pharmaceutical compounds and related ...ated intellectual property., Metathesis catalysts ...
...ewswire-USNewswire/ -- The,following statement may...n for the Advancement of Medical Research (CAMR): ...sident Bush once,again used the stroke of his veto...ific and medical research, as well as endanger,the...le. His,executive order directing NIH to continue ...
Other Medicine Technology:Materia Licenses Metathesis Catalyst Platform to Eisai 2President Bush Ignores America's Plea for Support of Stem Cell,Research 2
Rhoton Curettes, titanium, length 191 mm, straight.
Castroviejo "HM" Micro Needle Holder with Tungsten-Carbide Inserts, with catch. Serrated.
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Medicine Products: